Pseudomyxoma Peritonei
What's New
Last Posted: Aug 05, 2023
- A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei.
Shigeki Kusamura, et al. Biomedicines 2023 0 (7) - Genomic Landscape of Appendiceal Neoplasms.
Ang Celina S-P, et al. JCO precision oncology 2020 0 - Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.
Pengelly Reuben J, et al. The Journal of molecular diagnostics : JMD 2018 0 (5) 635-642 - Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
Yan Fengcai, et al. Human pathology 2020 0 9-18 - The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
Wang Bing, et al. International journal of cancer 2021 0 (8) 2036-2047 - Rapid recurrence of a ruptured mucinous borderline ovarian tumor harboring K-RAS mutation followed by progression into anaplastic carcinoma with TP53 mutation.
Yang Yang, et al. Heliyon 2022 0 (10) e10877 - KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing.
Matson Daniel R, et al. The American journal of case reports 2017 5 558-562 - Toward the molecular dissection of peritoneal pseudomyxoma.
Pietrantonio F, et al. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2016 8 - GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
Pietrantonio Filippo, et al. Journal of translational medicine 2016 0 (1) 125 - Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.
Liu Xiaoying, et al. Clinical chemistry 2014 7 (7) 1004-11 - Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms.
Nishikawa G, et al. British journal of cancer 2013 3 (4) 951-8 - Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
Shetty S, et al. The Journal of surgical research 2012 11 - Pseudomyxoma peritonei
From NCATS Genetic and Rare Diseases Information Center
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: